Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Yifan Pharmaceutical Co., Ltd.
  6. Summary
    002019   CNE000001K65

YIFAN PHARMACEUTICAL CO., LTD.

(002019)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shenzhen Stock Exchange
05/12/2022 05/13/2022 05/16/2022 05/17/2022 05/18/2022 Date
13.12 13.2 12.99 12.83 12.68 Last
7217723 6984995 5662953 5735767 5710080 Volume
-0.61% +0.61% -1.59% -1.23% -1.17% Change
Estimated financial data (e)
Sales 2022 5 268 M 780 M 780 M
Net income 2022 820 M 121 M 121 M
Net Debt 2022 - - -
P/E ratio 2022 19,2x
Yield 2022 -
Sales 2023 5 490 M 813 M 813 M
Net income 2023 874 M 129 M 129 M
Net Debt 2023 - - -
P/E ratio 2023 17,9x
Yield 2023 -
Capitalization 15 648 M 2 317 M 2 317 M
Capi. / Sales 2022 2,97x
Capi. / Sales 2023 2,85x
Nbr of Employees 4 285
Free-Float 57,2%
More Financials
Company
YIFAN XINFU PHARMACEUTICAL CO.,LTD, is a China-based company primarily engaged in production and sale of polymer materials. The Company operates in three segments, including Pharmaceuticals, Pharmaceutical Raw Material and Intermediates, as well as Polymer Materials. The Company's main products include D-calcium pantothenate, D- panthenol, poly butylenes succinate and others. The Company distributes its products in... 
Read more
Sector
Pharmaceuticals
Calendar
08/31Earnings Release
More about the company
Ratings of Yifan Pharmaceutical Co., Ltd.
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about YIFAN PHARMACEUTICAL CO., LTD.
04/28Yifan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended Mar..
CI
04/13Yifan Pharmaceutical Forgoes Final Dividend as 2021 Profit Plunges 71%
MT
04/12Yifan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended Decembe..
CI
2021Tranche Update on Yifan Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on Aug..
CI
2021Yifan Pharmaceutical Co., Ltd.'s Equity Buyback announced on August 30, 2021, has expir..
CI
2021China Rolls Out New Rules to Fight Monopoly in API Drugmaking Market
MT
2021Yifan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended Septe..
CI
2021Tranche Update on Yifan Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on Aug..
CI
2021Yifan Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 150 million worth of..
CI
2021Yifan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30..
CI
2021Yifan Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
CI
2021Yifan Pharmaceutical Co., Ltd. Announces to Implement Final Cash Distribution Plan A Sh..
CI
2021Yifan Pharmaceutical Co., Ltd. Approves Cash Dividend for 2020
CI
2021Yifan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended Mar..
CI
2021Yifan Pharmaceutical Co., Ltd. Announces the Profit Distribution Proposal for 2020
CI
More news
News in other languages on YIFAN PHARMACEUTICAL CO., LTD.
04/28Yifan Pharmaceutical Co., Ltd. annonce ses résultats pour le premier trimestre clos le ..
04/13Yifan Pharmaceutical renonce à son dernier dividende alors que le bénéfice de 2021 plon..
04/12Yifan Pharmaceutical Co., Ltd. annonce ses résultats pour l'année complète se terminant..
2021Yifan Pharmaceutical Co., Ltd. annonce la mise en œuvre d'un plan final de distribution..
2021Yifan Pharmaceutical Co., Ltd. approuve un dividende en espèces pour 2020. approuve le ..
More news
Chart YIFAN PHARMACEUTICAL CO., LTD.
Duration : Period :
Yifan Pharmaceutical Co., Ltd. Technical Analysis Chart | 002019 | CNE000001K65 | MarketScreener
Technical analysis trends YIFAN PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 12,68
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Xian Feng Cheng Chairman
Hai Xia Yu Chief Financial Officer
Guo Han Xu Deputy General Manager
Genhong Cheng Independent Director
Xin Tu Lei Independent Director
Sector and Competitors
1st jan.Capi. (M$)
YIFAN PHARMACEUTICAL CO., LTD.-28.04%2 350
SUN PHARMACEUTICAL INDUSTRIES LTD.5.45%27 620
OTSUKA HOLDINGS CO., LTD.6.67%18 647
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.-9.34%15 284
ONO PHARMACEUTICAL CO., LTD.19.29%12 860
CIPLA LIMITED-0.65%9 769